STOCK TITAN

Bio-Techne Declares Dividend

(Neutral)
Tags
dividends

Bio-Techne (NASDAQ: TECH) declared a quarterly cash dividend of $0.08 per share for the quarter ended June 30, 2026. The dividend is payable on August 28, 2026 to shareholders of record as of August 17, 2026. The Board will review future dividends quarterly.

Loading...
Loading translation...

Positive

  • $0.08 per-share quarterly cash dividend declared for quarter ended June 30, 2026
  • Dividend payable on August 28, 2026 to shareholders of record on August 17, 2026
  • Company reports fiscal year 2026 net sales of over $1.2 billion

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 17, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Bio–Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high–quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer–focused brands: R&D Systems™, Bio–Techne Spatial™, and Bio–Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision–making. Bio–Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedInX, or YouTube

Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact: 

David Clair, Vice President, Investor Relations


David.Clair@bio-techne.com


612-656-4416

Bio-Techne

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302849066.html

SOURCE Bio-Techne Corporation

FAQ

What dividend did Bio-Techne (NASDAQ: TECH) declare on August 12, 2026?

Bio-Techne declared a quarterly cash dividend of $0.08 per share. According to Bio-Techne, this dividend applies to the quarter ended June 30, 2026, and reflects the Board’s ongoing practice of considering cash dividends on a quarterly basis.

When is the Bio-Techne (TECH) August 2026 dividend record date and payment date?

Bio-Techne set August 17, 2026 as the shareholder record date and August 28, 2026 as the payment date. According to Bio-Techne, all common shareholders of record on August 17, 2026 will receive the $0.08 per-share dividend.

How often does Bio-Techne (TECH) plan to consider future cash dividends?

Bio-Techne’s Board will consider future cash dividends on a quarterly basis. According to Bio-Techne, each future dividend decision will be reviewed by the Board, meaning ongoing payouts are contemplated but not guaranteed or specified beyond this declared $0.08 dividend.

What were Bio-Techne (TECH) net sales in fiscal year 2026?

Bio-Techne generated over $1.2 billion in net sales in fiscal year 2026. According to Bio-Techne, this revenue came from its global life sciences operations, including reagents, analytical instruments, and precision diagnostics sold to research, biopharma, biotech, and clinical lab customers.

How large is Bio-Techne’s (TECH) global operation and workforce in 2026?

Bio-Techne operates in 34 locations worldwide and employs approximately 3,000 people. According to Bio-Techne, its global footprint supports more than 500,000 products serving academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories across multiple regions.

What products and brands support Bio-Techne (TECH) dividend-paying business?

Bio-Techne’s dividend-paying business is built on over 500,000 products across three brands. According to Bio-Techne, R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics cover needs from discovery research through translational research to clinical decision-making, supporting recurring global demand.